Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

@article{Halmos2015RandomizedPI,
  title={Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.},
  author={Balazs Halmos and Nathan A. Pennell and Pingfu Fu and Shumaila Saad and Shirish M. Gadgeel and Gregory Alan Otterson and Tarek Abdel Malak Mekhail and Michael L Snell and John Philip Kuebler and Neelesh Sharma and Afshin Dowlati},
  journal={The oncologist},
  year={2015},
  volume={20 11},
  pages={1298-303}
}
BACKGROUND Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, acquired resistance develops uniformly and the benefit of continuation of EGFR TKI therapy beyond progression remains unclear. MATERIALS AND METHODS This was a randomized phase II study of chemotherapy (arm A: pemetrexed or docetaxel) versus chemotherapy plus erlotinib (ERL) (arm B) in patients with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS